Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients (MONARCH)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Janssen-Cilag S.p.A.
ClinicalTrials.gov Identifier:
NCT01391013
First received: June 23, 2011
Last updated: May 22, 2013
Last verified: May 2013
Results First Received: February 13, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Human Immunodeficiency Virus 1
Interventions: Drug: Darunavir(DRV)
Drug: Ritonavir
Drug: 2 nucleoside reverse transcriptase inhibitors (NRTIs)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
30 participants were enrolled at a single site in Italy.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
30 participants were randomly assigned to 2 treatment groups (15 participants in each group) and all participants received the study medication.

Reporting Groups
  Description
Monotherapy 2 tablets of darunavir (2 X 400 mg) and 1 tablet ritonavir (100 mg) administered once daily
Combination Therapy 2 tablets of darunavir (2 X 400 mg) and 1 tablet ritonavir (100 mg) once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs)

Participant Flow:   Overall Study
    Monotherapy     Combination Therapy  
STARTED     15     15  
COMPLETED     15     15  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Monotherapy 2 tablets of darunavir (2 X 400 mg) and 1 tablet ritonavir (100 mg) administered once daily
Combination Therapy 2 tablets of darunavir (2 X 400 mg) and 1 tablet ritonavir (100 mg) once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Total Total of all reporting groups

Baseline Measures
    Monotherapy     Combination Therapy     Total  
Number of Participants  
[units: participants]
  15     15     30  
Age  
[units: Years]
Median ( Inter-Quartile Range )
  44.8  
  ( 34.5 to 55.1 )  
  43.0  
  ( 35.0 to 46.8 )  
  44.6  
  ( 35.0 to 47.4 )  
Gender  
[units: Participants]
     
Female     3     4     7  
Male     12     11     23  
Race/Ethnicity, Customized  
[units: Participants]
     
White     14     15     29  
Black     1     0     1  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline to Week 24 in Brachial Artery Flow Mediated Vasodilatation (FMD): Median Change in FMD (%)   [ Time Frame: Baseline (Day 1 of Week 1) to Week 24 ]

2.  Secondary:   Change From Baseline to Week 48 in Brachial Artery FMD: Median Change in FMD (%)   [ Time Frame: Baseline to Week 48 ]

3.  Secondary:   Number of Participants With a Human Immunodeficiency Virus- Ribonucleic Acid (HIV-RNA) Greater Than or Equal to 50 Copies/mL   [ Time Frame: Screening (Week -4), Week 1 (Day 1), Week 4, Week 12, Week 24, Week 36, Week 48, and follow-up (Week 52) ]

4.  Secondary:   Change From Baseline to Week 48 in Circulating Endothelial Cells   [ Time Frame: Baseline to Week 48 ]

5.  Secondary:   Change From Baseline to Week 48 in Precursors of Circulating Endothelial Cells   [ Time Frame: Baseline to Week 48 ]

6.  Secondary:   Change From Baseline in Mean Low-density Lipoprotein (LDL) Cholesterol at Week 24 and Week 48: Median Change in LDL   [ Time Frame: Baseline (Day1 of Week 1), Week 24, and Week 48 ]

7.  Secondary:   Change From Baseline in Mean High-density Lipoprotein (HDL) Cholesterol at Week 24 and Week 48: Median Change in HDL   [ Time Frame: Baseline, Week 24, and Week 48 ]

8.  Secondary:   Change From Baseline in Mean Triglycerides at Week 24 and Week 48: Median Change in Triglycerides   [ Time Frame: Baseline, Week 24, and Week 48 ]

9.  Secondary:   Change From Baseline in Insulin Sensitivity at Week 24 and Week 48: Median Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)   [ Time Frame: Baseline, Week 24, and Week 48 ]

10.  Secondary:   Change From Baseline in Mean Framingham Risk Score at Week 24 and Week 48: Medican Change in Framingham Risk Score   [ Time Frame: Baseline, Week 24, and Week 48 ]

11.  Secondary:   Change From Baseline to Week 48 in Leg Fat Content: Median Change in Leg Fat (Total)   [ Time Frame: Baseline to Week 48 ]

12.  Secondary:   Change From Baseline to Week 48 in Visceral Fat Content in Abdomen: Median Change in Visceral Abdominal Tissue (VAT)   [ Time Frame: Baseline to Week 48 ]

13.  Secondary:   Change From Baseline to Week 48 in Femoral Neck T Score: Median Change in Femoral Neck T Score   [ Time Frame: Baseline to Week 48 ]

14.  Secondary:   Change From Baseline to Week 48 in Femoral Neck Z Score: Median Change in Femoral Neck Z Score   [ Time Frame: Baseline to Week 48 ]

15.  Secondary:   Change From Baseline to Week 48 in Lumbar T Score: Median Change in Lumbar T Score   [ Time Frame: Baseline to Week 48 ]

16.  Secondary:   Change From Baseline to Week 48 in Lumbar Z Score: Median Change in Lumbar Z Score   [ Time Frame: Baseline to Week 48 ]

17.  Secondary:   Change From Baseline in Cluster of Differentiation 4 (CD4) Count Over Week 48   [ Time Frame: Screening (Week -4), Week 1 (Day 1), Week 4, Week 12, Week 24, Week 36, Week 48, and follow-up (Week 52) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information